Online citations, reference lists, and bibliographies.
← Back to Search

Topical Tacrolimus 0.03% Ointment For Intractable Allergic Conjunctivitis: An Open-Label Pilot Study

Liat Attas-Fox, Y. Barkana, Vladimir Iskhakov, Svetlana Rayvich, Y. Gerber, Y. Morad, I. Avni, D. Zadok
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: To evaluate the feasibility of tacrolimus 0.03% dermatological ointment (Protopic) in the treatment of intractable allergic conjunctivitis. Methods: Twenty patients (mean age 10.8 years, range 6–26) with intractable allergic conjunctivitis were enrolled in an open-label study. Tacrolimus 0.03% ointment was applied into the conjunctival sac of both eyes twice daily for 8 weeks, followed by a 2-week washout period. Other ocular medications were discontinued. Conjunctivitis severity was recorded with a composite subjective/objective score (chemosis, tarsal papillary size, corneal staining, tearing, itching, and photophobia) at baseline, week 8, and after washout. Tacrolimus blood levels were measured at 2 weeks. Results: Statistically significant improvement in all categories of the conjunctivitis score was observed between baseline and the week 8 examination (p < 0.001). Adverse events were limited to local burning in one patient who discontinued treatment. Blood tacrolimus levels were mostly undetectable. Conclusions: Application of tacrolimus 0.03% dermatological ointment into the conjunctival sac appears to be effective, well tolerated, and safe in the treatment of allergic conjunctivitis refractory to traditional treatment.
This paper references
10.1076/ceyr.26.5.319.15437
Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis
S. Trocme (2003)
10.1016/J.OPHTHA.2003.05.035
A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
E. Akpek (2004)
10.1097/00130832-200310000-00012
Fibrosis in ocular allergic inflammation: recent concepts in the pathogenesis of ocular allergy
A. Solomon (2003)
10.1136/bjo.2005.070888
Topical ciclosporin in the treatment of ocular surface disorders
S. Tatlıpınar (2005)
10.1016/J.JACI.2003.10.065
Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment.
P. Vichyanond (2004)
10.1001/ARCHOPHT.1990.01070030090035
Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis.
M. Abelson (1990)
10.2340/00015555-0167
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
A. Remitz (2007)
10.1016/S0161-6420(91)32154-7
Immunopathology of atopic keratoconjunctivitis.
C. S. Foster (1991)
10.1111/J.1600-0420.2006.00699.X
Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study.
Hannele M Virtanen (2006)
Tacrolimus, a new immunosuppressantA review of the literature
MA Hooks (1994)
Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group.
S. Reitamo (2000)
10.1016/S0002-9394(02)01982-7
Topical tacrolimus treatment of atopic eyelid disease.
Sarah M Rikkers (2003)
10.1016/J.JAAD.2005.04.063
Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients.
J. Koo (2005)
Topical cyclosporine in the treatment of ocular surface disorders
S Tatlipinar (2005)
10.1016/S0161-6420(97)30223-1
Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
S. Bonini (1997)
10.1007/s00417-001-0424-0
Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506
K. Nishino (2002)
10.1001/ARCHDERM.136.8.999
Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis
S. Reitamo (2000)
Tacrolimus ointment in the treatment of eyelid dermatitis.
A. Freeman (2004)
Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.
A. Cheng (2006)
10.1016/0002-9394(86)90819-6
Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis.
D. Benezra (1986)
10.7164/ANTIBIOTICS.40.1256
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.
T. Kino (1987)
10.1016/S0140-6736(05)65512-2
Tacrolimus concentrations in blood during topical treatment of atopic dermatitis
M. Kawashima (1996)
10.1177/106002809402800414
Tacrolimus, a New Immunosuppressant—A Review of the Literature
M. Hooks (1994)
10.7164/antibiotics.40.1256
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.
T. Kino (1987)
10.1093/NDT/15.12.1916
Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A.
W. Almawi (2000)



This paper is referenced by
10.1097/ICU.0b013e32832c9007
Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients
R. Hazin (2009)
10.1097/ACI.0000000000000089
Topical immunomodulators in the management of allergic eye diseases
N. Erdinest (2014)
10.1111/ddg.13809_g
Management der Dupilumab‐assoziierten Konjunktivitis beim atopischen Ekzem
N. Aszodi (2019)
10.1007/s40266-019-00676-7
Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly
E. Ridolo (2019)
10.1016/j.jaad.2013.10.036
Atopic keratoconjunctivitis: A review.
J. Chen (2014)
Queratoconjuntivitis vernal refractaria: ¿es el tacrolimus una opción terapéutica? Estudio prospectivo
R. Ramírez (2012)
10.1097/ICO.0000000000000918
Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis
S. Chatterjee (2016)
10.3109/02713683.2015.1082187
Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test
A. Pastor-Clerigues (2016)
10.1016/B978-1-4557-2876-3.00017-1
17 – Treatment of Allergic Eye Disease
Amy T. Kelmenson (2013)
10.4103/0976-9668.166051
Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis
A. K. Hazarika (2015)
10.1542/peds.2016-2069
Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review
Jing Li (2018)
10.1111/all.12009
Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface
A. Leonardi (2012)
10.17352/atte.000006
The cellular inflammatory response associated with sulfur mustard induced delayed limbal stem cell deficiency and evaluation of tacrolimus treatment
E. Berg (2019)
10.1016/j.ajo.2013.10.006
Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
A. Al-Amri (2014)
10.1089/jop.2009.0087
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
Y. Ohashi (2010)
10.1177/2040622315612745
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management
S. Ackerman (2016)
10.1007/s40267-019-00694-w
Act quickly when treating atopic keratoconjunctivitis to avoid adverse outcomes
Adis Medical Writers (2020)
10.4137/OED.S0
The Use of Topical Tacrolimus 0.1% Skin Ointment for Anterior Segment Conditions: A Case Series
P. Abeysiri (2010)
10.1016/J.OFTAL.2012.09.023
Tracolimus en el tratamiento de la queratoconjuntivitis atópica
A. Ferreiro (2013)
10.2478/V10181-012-0104-5
Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs.
I. Balicki (2012)
10.1007/978-3-030-14092-2_62
Evaluation of the Anophthalmic Socket
David R. Jordan (2019)
10.1016/J.OFTALE.2013.09.013
Tacrolimus in the treatment of atopic kerato-conjunctivitis
A. Ferreiro (2013)
Dry Eye: an Inflammatory Ocular Disease
Michelle Hessen (2014)
10.1007/s00417-013-2333-4
Topical tacrolimus for the management of acute allergic conjunctivitis in a mouse model
I. Barequet (2013)
Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis
T. Wakamatsu (2011)
10.1517/14728210903103818
Emerging drugs for conjunctivitis
C. Origlieri (2009)
10.2174/187221311794474883
Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.
G. P. Mishra (2011)
10.5935/0004-2749.20190026
Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis.
Guilherme Gubert Müller (2019)
10.1007/s40123-016-0074-2
Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature
S. Doan (2016)
10.1201/B13153-16
Management of Ocular Allergy
Laura Motterle (2012)
10.1016/J.REVAL.2014.05.005
Allergie oculaire : reconnaître et diagnostiquer les réactions d’hypersensibilité de la surface oculaire
A. Leonardi (2014)
10.5935/0004-2749.20170052
Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children.
Vera Lucia Liendo (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar